Home Newsfeeds Sidus Space Granted Notice Of Allowance For U.S. Patent Titled ‘HIGH-LOAD VACUUM CHAMBER MOTION FEEDTHROUGH SYSTEM AND METHODS’

Sidus Space Granted Notice Of Allowance For U.S. Patent Titled ‘HIGH-LOAD VACUUM CHAMBER MOTION FEEDTHROUGH SYSTEM AND METHODS’

https://twitter.com/PatentGrants/status/1557396471019737090

byBenzinga Newsdesk

August 10, 2022

1 minute read

$SIDU Sidus Space (formerly Craig Technologies Aerospace Solutions) has received a Notice of Allowance for its US patent application 17/133,744 titled "HIGH-LOAD VACUUM CHAMBER MOTION FEEDTHROUGH SYSTEM AND METHODS". Invention made under NASA contract. pic.twitter.com/L4KtCez3Jy

— PatentGrants (@PatentGrants) August 10, 2022

BIO-key Sees FY22 Revenue $7M-$9M

By Benzinga Newsdesk

November 14, 6:00 PM

Outlook “We expect a strong close to the year, however, given our slower than expected sales so far this year, we now expect full-year revenues of $7M to $9M in 2022, representing growth of 37% to 76% over 2021

BKYI

RBC Capital Maintains Sector Perform on BioCryst Pharmaceuticals, Lowers Price Target to $13

By Benzinga Newsdesk

November 2, 8:22 AM

RBC Capital analyst Brian Abrahams maintains BioCryst Pharmaceuticals (NASDAQ:BCRX) with a Sector Perform and lowers the price target from $14 to $13.

BCRX

Anthony Scaramucci Sees Fed ‘Declaring Victory’ At 4%-5% Inflation: ‘If I’m Right…There’ll Be Lot Of Short Covering In Crypto’

By Bhavik Nair

January 26, 1:56 AM

Anthony Scaramucci, the founder of SkyBridge Capital, reportedly said he expects the Federal Reserve to pause its rate hike campaign before inflation hits the 2% goal, which woul

BTC

Morgan Stanley Maintains Equal-Weight on US Foods Hldg, Lowers Price Target to $39

By Benzinga Newsdesk

July 18, 10:10 AM

Morgan Stanley analyst John Glass maintains US Foods Hldg (NYSE:USFD) with a Equal-Weight and lowers the price target from $42 to $39.

USFD

Sidus Space Granted Notice Of Allowance For U.S. Patent Titled ‘HIGH-LOAD VACUUM CHAMBER MOTION FEEDTHROUGH SYSTEM AND METHODS’

Related Posts

BIO-key Sees FY22 Revenue $7M-$9M

RBC Capital Maintains Sector Perform on BioCryst Pharmaceuticals, Lowers Price Target to $13

Anthony Scaramucci Sees Fed ‘Declaring Victory’ At 4%-5% Inflation: ‘If I’m Right…There’ll Be Lot Of Short Covering In Crypto’

Morgan Stanley Maintains Equal-Weight on US Foods Hldg, Lowers Price Target to $39